Bellicum Pharmaceuticals is a privately held biotherapeutics company headquartered in Houston, Texas. Founded in 2004 by Baylor College of Medicine Professors Kevin Slawin, MD and David Spencer, PhD, to commercialize Chemical Induction of Dimerization (CID) technology, the company became fully operational in 2006 with the addition of CEO Tom Farrell, completion of a seed financing, and execution of a core license agreement with ARIAD Pharmaceuticals. They have two programs in clinical development, and have assembled a world class team of advisors and consultants.Their DeCIDe therapeutic vaccines for cancer and infectious diseases give the physician control of CD40 and Toll-Like Receptor (TLR) signaling pathways in dendritic cells, thereby overriding feedback mechanisms in the immune system which would otherwise limit the effectiveness of the vaccine. The drug is administered 24 hours after the vaccine, when the vaccine cells have migrated to the patient’s lymph nodes. First generation autologous DeCIDe vaccines are paving the way for a second generation that can be supplied off the shelf, without the need for autologous cell processing. Their CaspaCIDe self destruct switch gives the physician control of caspase 9 signaling, which directly activates apoptosis (programmed cell death) in a context-specific manner, allowing preferential elimination of CaspaCIDe cell subpopulations. The drug is administered when necessary to eliminate transplanted cells should they become harmful, or after they have served their purpose.